Neihulizumab

Drug Profile

Neihulizumab

Alternative Names: AbGn-168; AbGn-168H; Antibody-168

Latest Information Update: 11 Jul 2016

Price : $50

At a glance

  • Originator AbGenomics Corporation
  • Developer AbGenomics Corporation; Boehringer Ingelheim; Stanford University
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Apoprotein stimulants; Apoptosis stimulants; P-selectin ligand protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Psoriatic arthritis
  • Phase I/II Graft-versus-host disease
  • Phase I Type 1 diabetes mellitus
  • Discontinued Plaque psoriasis

Most Recent Events

  • 31 May 2016 Discontinued - Phase-II for Plaque psoriasis in USA (IV)
  • 31 May 2016 Phase-I clinical trials in Type-1 diabetes mellitus (Parenteral)
  • 02 May 2016 AbGenomics withdraws a planned phase II trial for Graft-versus-host disease (Steroid refractory) prior to enrolment in USA (IV) (NCT02694770)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top